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Abstract
The ABC transporters multidrug resistance associated protein 2 (MRP2) and breast cancer
resistance protein (BCRP) are of interest in drug development, since they affect the phar-
macokinetics of several drugs. Membrane vesicle transport assays are widely used to
study interactions with these proteins. Since albumin has been found to affect the kinetics
of metabolic enzymes in similar membrane preparations, we investigated whether albumin
affects the kinetic parameters of efflux transport. We found that albumin increased the Vmax
of 5(6)-carboxy-2’,7’-dichlorofluorescein (CDCF) and estradiol-17-β-D-glucuronide uptake
into MRP2 vesicles in the presence of 0.1% bovine serum albumin (BSA) by 2 and 1.5-fold,
respectively, while BSA increased Lucifer yellow uptake by 30% in BCRP vesicles. Km val-
ues increased slightly, but the change was not statistically significant. The effect of BSA on
substrate uptake was dependent on the vesicle amount, while increasing BSA concentra-
tion did not significantly improve substrate uptake. These results indicate a minor effect of
albumin on MRP2 and BCRP, but it should be considered if albumin is added to transporter
assays for example as a solubilizer, since the effect may be substrate or transporter
specific.
Introduction
ATP-binding cassette proteins, also known as ABC proteins or ABC transporters, are a large
group of membrane proteins that translocate a wide range of substrates across various biologi-
cal membranes using ATP as energy [1]. ABC transporters have an important role in the
disposition and elimination of endogenous compounds and the defense of the cell against
xenobiotics. Due to their expression in many pharmacokinetically important tissues, some of
these transporters can also affect the pharmacokinetics of drugs. Among the ABC transporters
implicated in drug transport are the multidrug resistance associated protein 2 (MRP2) and the
breast cancer resistance protein (BCRP) or ABCC2 and ABCG2, respectively, according to
ABC nomenclature. They are involved in drug efflux in several tissues, including the liver,
intestine and kidney [2–5]. MRP2 has an important role in the excretion of endogenousmetab-
olites of estradiol and bilirubin. Dysfunctionof the protein results in the accumulation of
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bilirubin conjugates, which is known as Dubin-Johnson syndrome [6, 7]. In addition to the
physiological substrates, MRP2 is also associated with the excretion of anionic drugs and their
glucuronide and glutathione conjugates (reviewed in [8]). Changes in MRP2 function or
expression can cause altered exposure to drugs as has been shown for example for pravastatin
[9, 10] and methotrexate [11]. Althoughmany compounds can inhibit MRP2, so far there has
been no evidence of clinical drug-drug interactions or MRP2-mediated drug induced liver tox-
icity. Therefore it is currently recommended that interaction of an investigational new drug
with MRP2 is studiedmainly if in vivo results indicate problems with hyperbilirubinemia [12].
BCRP is a half-transporter that was named based on its identification in a breast cancer cell
line [13]. In addition to its chemotherapeutic substrates, BCRP is known to transport drugs
such as sulfasalazine and rosuvastatin and is inhibited by several immunosuppressants, calcium
channel blockers and HIV protease inhibitors (for a recent review see [14]). Inhibition of
BCRP has been shown to increase exposure to rosuvastatin and topotecan in clinical trials [14,
15]. The Q141K genetic variant resulting in decreased expression of BCRP has been linked to
altered exposure to drugs such as statins [16] as well as incidence of gout through decreased
excretion of uric acid [17, 18]. Due to this influence on pharmacokinetics, BCRP is one of the
transporters included in drug-drug interaction guidelines of the United States Food and Drug
Administration and the European Medicines Agency [19, 20].
There are several ways of studying drug transport in vitro and they have been reviewed in
detail by Brouwer et al. [21]. These include uptake or permeability studies using intact cells or
cell monolayers overexpressing the transporter of interest, studies in sandwich cultured hepa-
tocytes as well as uptake into inverted membrane vesicles. The methods differ in their level of
complexity and the type of information they give and are therefore at best used to complement
each other.
Inverted membrane vesicles with overexpressed transporters allow a way to study the inter-
action and kinetics of a compound with direct access of the compound to the transporter bind-
ing site [21, 22]. In the vesicular transport assay, uptake of substrates is quantified by
measuring their accumulation into inside-out oriented membrane vesicles. These vesicle-based
assays allow a higher throughput and convenience compared to whole cell assays since they
can be prepared in large batches and cryopreserved for later use. The interaction data generated
in the vesicle system can be used to predict the in vivo transporter-mediated disposition and
possible drug-drug interactions. However, the reliability and usefulness of vesicle-based predic-
tions remains to be clarified [21].
Similar membrane vesicle preparations are used to study the interaction of drugs with
metabolizing enzymes, like UDP-glucuronosyltransferase (UGT) and Cytochrome P450. How-
ever, in vitro based extrapolations of clearance using these vesicles tend to underpredict in vivo
clearance [23]. One factor seen to increase the activity of UGTs and CYP 450 metabolic
enzymes in vitro and thus alleviate underpredictionhas been the use of human or bovine
serum albumin (BSA) in metabolic assays. For example Kilford et al. [24] showed improved
predictions of intrinsic clearance for 8 out of 10 drugsmetabolized by CYPs and/or UGTs
mainly through CYP2C9 and UGT2B7 effects when 2% BSA was included in assays [24]. Bene-
ficial effects of albumin on clearance predictions have also been demonstrated for compounds
such as phenytoin [25–27] and lamotrigine [28].
Due to the similarity of the preparations used to study the metabolic enzymes and the trans-
porters that may affect drug pharmacokinetics, we investigated whether BSA has an effect on
the observedATP-dependent transport of the ABC transportersMRP2 and BCRP in the vesic-
ular transport assay and if the effect could potentially be mediated by fatty acids as has been
proposed for the metabolic enzymes.
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Materials and Methods
Materials
Human BCRP cDNA, pcDNA3-BCRP (R482T mutant)[13] and human MRP2 cDNA
(pGEM3-MRP2) corresponding to NCBI Genbank accession number entry U49248, were kind
gifts from Dr Douglas Ross (University of Maryland Greenbaum Cancer Center) and Dr Piet
Borst (The Netherlands Cancer institute, Netherlands), respectively. Essentially fatty acid free
bovine serum album (BSA) was purchased from Sigma-Aldrich (St. Louis, MO). The water sol-
uble cholesterol/RAMEB (randomly methylated beta-cyclodextrin)complex was obtained
from Cyclolab Ltd (Hungary).
Vesicle preparations
Recombinant baculovirus for expressing MRP2, BCRP and β-galactosidase (for control mem-
branes) were created according to the Bac-to-bac1 Baculovirus Expression system protocol
(Invitrogen Life Technologies, Waltham, MA). The MRP2 and β-galactosidase pFastBacI plas-
mids were constructed as described in. [29]. The BCRP-pFastBacI plasmid was generated by
subcloning either BCRP cDNA from pcDNA3-BCRP into the BamHI/XhoI site. The BCRP
cDNA was converted to wildtype BCRP (corresponding to Uniprot entry Q9UNQ0) with
QuikChange1 Lightning Site-DirectedMutagenesis Kit and primers 5´-ctgttatctgatttattacccat-
gaggatgttaccaagtattatatttacc-3´ and 5´-ggtaaatataatacttggtaacatcctcatgggtaataaatcagataacag-3´.
The bacmids used to transfect the Sf9 insect cells (from Spodoptera frugiperda) were con-
structed in Eschericia coli DH10Bac cells.
Sf9 cells were cultured in suspension in HyQ SFX-InsectMP medium (Thermo Fisher Sci-
entific,Waltham, MA) supplemented with 5% fetal bovine serum.Cells were infected with
recombinant baculovirus-DNA and harvested and washed with phosphate buffered saline
(PBS) approximately 60 hours after infection.Membranes were prepared from the cells using a
modification of the Chu et al. [30] method as described in detail in [29]. To form the vesicles,
the suspension was passed 10 times through a LIPEX™ Extruder (Northern Lipids Inc., Bur-
naby, BC, Canada) or 20 times through a 27 gauge needle. Protein concentration was measured
using the Bio-Rad protein assay (Bio-Rad Laboratories Inc., Hercules, CA). Vesicles were
stored at -75°C at protein concentrations of 3.5–5 mg/ml.
To improve the dynamic range of the assay, BCRPmembranes were loaded with cholesterol
similarly to Telbisz et al. [31], by incubating the membranes on ice for 20 minutes in the pres-
ence of the water-soluble cholesterol complex at a total concentration of 2.5 mM cholesterol.
Excess of the complex was removed by diluting the mixture and centrifugation at 100 000 g at
+ 4°C for 1 h 15 min. The remaining membrane pellet was resuspended in membrane buffer
(50 mM Tris–HCl pH 7.0, 50 mMmannitol, 2 mM EGTA). The resulting cholesterol concen-
tration in the vesicles was roughly 100 μg/mg total protein as measured using the Amplex Red
Cholesterol kit (Life Technologies, Carlsbad, CA).
Substrate binding to BSA
The fraction of unbound substrate in the presence of BSA was studied with the rapid equilib-
rium dialysis (RED) device (Thermo Scientific,Waltham, MA). In the RED system, two cham-
bers in a well are separated with dialysis membrane. The transporter substrate (CDCF, E217βG
or LY) was placed in the donor chamber in assay buffer with control membrane vesicles in the
presence or absence of BSA to mimic the VT assay conditions. The final concentrations of BSA
was 0.1% or 1.0%. Plain assay buffer was pipetted into the receiver chambers of all wells until
the liquid level of both chambers was equal. For solubility reasons, the final composition of
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assay buffer included dimethyl sulfoxide (DMSO) up to 1.5% depending on substrate. Samples
were incubated at 37°C on an orbital shaker. After 7 hour incubation, a small aliquot was col-
lected from each receiver chamber for analysis. The relative fraction of unbound substrate (fu)
was calculated as the ratio of concentrations in the receiver chambers from the samples with
and without BSA.
Vesicular transport (VT) assay
The effect of BSA was studied with three different substrates; 5(6)-carboxy-2,7-dichlorofluores-
cein (CDCF), and estradiol-17-β-D-glucuronide (E217βG) were used with MRP2 and Lucifer
yellow (LY) with BCRP. The assay was carried out as a modification of the PREDIVEZ™ Vesic-
ular Transport Kit protocol (SOLVO Biotechnology, Szeged, Hungary). In short, vesicle stocks
were thawed and diluted with assay buffer (40 mMMOPS–Tris pH 7.0, 60 mMKCl, 6 mM
MgCl2). The substrate at various concentrations was added subsequently with 0.1% or 1.0%
BSA (w/v), or an equivalent volume of deionizedwater for the control. 1.9 mM glutathione
(GSH) was also included in the MRP2 assays. The well plate was preincubated at 37°C for 5–10
minutes after which half of the samples were treated with prewarmed plain assay buffer (non-
ATP control), and the other half with prewarmedMg-ATP-solution (final concentration 4
mM). Samples were subsequently incubated at 37°C for 8 minutes (E217βG), 10 minutes (LY)
and 30 minutes (CDCF) to coincide with the linear phase of uptake. Transport was terminated
with ice cold washing buffer (40 mMMOPS-Tris pH 7.0 and 70 mMKCl). Samples were
quickly transferred to the MultiScreenHTS-FBPlate Glass fiber 1.0 μm / 0.65 μm Durapore fil-
ter plate (Millipore, Molsheim, France). Wells were immediately washed five times with 200 μl
washing buffer and dried. 0.1 M sodiumhydroxide was used to elute LY and CDCF, which
were detected by fluorescencemeasurement. E217βG and was eluted with 0.1 M ammonium
hydroxide and analyzed with mass spectrometry.
The modulation of MRP2 and BCRP uptake by fatty acid oleic acid was also studied with
the VT assay. The assay was performed as above, but oleic acid was present at various concen-
trations. The probe concentration in these studies was 5 μM for CDCF and 50 μM for LY. Plain
vehicle (70% ethanol) was used as a control.
Membrane effects of oleic acid
Disruption of the membrane vesicles by oleic acid during the assay was evaluated using a modi-
fication of the VT assay. Vesicles were incubated with the substrates in the presence of ATP to
load the vesicles. ATP-dependent transport was stopped using 1.2 mM sodium orthovanadate.
Oleic acid or vehicle was added and after incubation for 10 min (LY) or 30 min (CDCF) the
samples were diluted with washing buffer, filtered and washed as usual. The incubation time
after stopping of the reaction was set as the same time that vesicles are incubated with oleic
acid in the corresponding inhibition assays for MRP2 and BCRP.
Analytical methods
CDCF and LY samples were measured with fluorometric detection using Varioskan Flash
(Thermo Scientific, Vantaa, Finland). The excitation and emission wavelengths used for CDCF
detectionwere 510 and 535 nm respectively. LY samples in 0.1 M sodium hydroxide were
treated with an equal volume of 0.1 M hydrochloric acid before fluorometric analysis and
detectedwith excitation at 430 nm and emission at 538 nm.
E217βG samples for the BSA binding studies were analyzed by ultra-performance liquid
chromatography (Acquity UPLC,Waters, Milford, MA). Acquity UPLC BEH Shield RP18
(130Å, 1.7 μm, 2.1 mm X 50 mm,Waters, Milford, MA) was used for E217βG separation.
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Acetonitrile and phosphate buffers were used as mobile phase and flow rate was 0.5 ml/min.
Samples were detected using UV/Vis spectroscopy using a wavelength of 218 nm for E217βG.
Quantitative analyses of E217βG vesicular transport assay samples were executed by ultra
performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) using a
Waters ACQUITYUPLC I Class (Waters, Milford, MA) combined with a Waters XevoTM
TQ-S MS triple quadrupole (Waters, Milford, MA). The UPLC system was equipped with a
sample manager (maintained at 10°C), a binary solvent manager and a column thermostat
(maintained at 26°C). Separations were performed on a 2.1 × 100 mm column, which was
packed with 1.8 μm particles (ACQUITYUPLCHSS T3 C18,Waters, Milford, MA). The flow
rate was 0.4 ml/min and the injection volume was 10 μl. Water with 0.1% formic acid (A) and
ACN with 0.1% formic acid (B) were used as the mobile phases for the gradient elution. The
gradient was as follows: from 0 to 3 min 5–100% B and from 3 to 7 min 100% B. Each run was
followed by a 2 min re-equilibration period under initial conditions (5% B).
Mass spectrometricmeasurements were carried out using ESI source in negative ion mode.
Capillary voltage was 1.5 kV, cone voltage 30 V. Desolvation temperature was set to 600°C,
while desolvation gas flow was 600 l/hr and cone gas flow 150 l/hr. To reach enough sensitivity
dwell time was set to 80 ms for the analyte and internal standards. Scan type was multiple reac-
tion monitoring (MRM) and monitored ions were 447.1> 74.8 (CE 25 eV) and 447.1> 271.1
(CE 30 eV) for E217βG and 348.9> 268.9 (CE 35 eV) for estrone sulfate and 205.2> 161.2
(CE 5 eV) for ibuprofen, which were used as internal standards.
Data analysis
ATP-dependent transport was calculated as the difference between uptake in the presence and
absence of ATP. All assays were performed in triplicates on a 96-well plate. Curve fitting to the
data was performedwith GraphPad Prism 6.04 (GraphPad Software Inc., La Jolla, CA). Sub-
strate data was fitted with the Michaelis-Menten equation
v ¼
Vmax½S
Km þ ½S
ð1Þ
where v is the velocity of ATP-dependent transport, Vmax is the maximal transport velocity, [S]
is the substrate concentration and Km is the Michaelis-Menten constant. In the case of E217βG,
which follows sigmoidal kinetics with MRP2 [32, 33], the equation was modifiedwith h for
Hill slope.
v ¼
Vmax½S
h
Km
h þ ½Sh
ð2Þ
Results from the kinetic studies are presented as relative transport values (%), which are cal-
culated by normalizing all data points to the fitted Vmax value of the control (0% BSA) and
shown with standard deviation (SD). The statistical significance in the difference betweenVmax
and Km values calculated in the presence and absence of BSA was analyzed in GraphPad Prism
using the extra-sum-of-squares F-test. The statistical significance in the difference between the
uptake rate of 0.1% and 1.0% BSA treated vesicles was analyzed in GraphPad Prism using the
unpaired t-test.
The oleic acid concentration required for 50% inhibition (IC50), was calculated from the
concentration-response data using four parameter logistic regression,
Response ¼ Responsemin þ
Responsemax   Responsemin
1þ ð
½I
IC50
Þ
h ð3Þ
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where response is the control normalizedATP-dependent uptake (%), Responsemin and
Responsemax represent the plateaus corresponding to minimal and maximal normalized uptake
(%), [I] is the concentration of inhibitor (μM), IC50 is the inhibitor concentration required for
a response half-way betweenminimal and maximal response (μM) and h is the Hill coefficient.
The Responsemin term was constrained to be larger than zero, where zero indicates full abolish-
ment of uptake.
Results
Substrate binding to BSA
BSA binds a broad range of compounds and may thus decrease the concentration of free substrate
in solution. In order to correct for the decrease in unbound concentration of the substrate in the
assay, we measured the binding to BSA in assay conditions. The substrates used in this study
showed none or low binding to 0.1% BSA at the concentrations studied (Table 1). CDCFwas the
only substrate to show a concentration dependent decrease in unbound concentrations in the
concentration range studied. At 1.0% BSA, the decrease in unbound concentrations of CDCFwas
more pronounced, but LY remained completely unbound regardless of higher amount of BSA
(Table 2). This binding of CDCF to 0.1% BSA was taken into account by correcting all concentra-
tion values with the average fu of 0.94. The CDCFbinding to 1.0% BSA was adjusted separately
for each concentration. The unbound concentrations for the other compounds were not adjusted
since the fu was close to 1.0 and no trend for concentration dependency could be seen.
The effect of BSA in the VT assay
The effect of BSA on MRP2 transport was examined with two commonly usedMRP2 sub-
strates, CDCF and E217βG [34, 35]. A significant change in the ATP-dependent uptake of the
Table 1. Substrate binding to 0.1% BSA as measured using equilibrium dialysis. The fu is calculated as the ratio of binding in the presence and
absence of 0.1% BSA and is shown with standard deviation (SD) (n = 3).
Substrate Concentration (μM) fu (± SD)
5(6)-Carboxy-2,7-dichlorofluorescein (CDCF) 1 0.92 (± 0.02)
5 0.94 (± 0.02)
50 0.96 (± 0.01)
Estradiol-17-β-D-glucuronide (E217βG) 15 0.96 (± 0.04)
50 1.00 (± 0.03)
150 0.98 (± 0.04)
Lucifer Yellow (LY) 20 0.98 (± 0.01)
200 0.98 (± 0.03)
doi:10.1371/journal.pone.0163886.t001
Table 2. Substrate binding to 1.0% BSA as measured using equilibrium dialysis. The fu is calculated as the ratio of binding in the presence and
absence of BSA and is shown with standard deviation (SD) (n = 3).
Substrate Concentration (μM) fu (± SD)
5(6)-Carboxy-2,7-dichlorofluorescein (CDCF) 5 0.43 (± 0.02)
50 0.53 (± 0.02)
200 0.73 (± 0.03)
Lucifer Yellow (LY) 5 1.03 (± 0.02)
50 1.01 (± 0.03)
200 1.03 (± 0.02)
doi:10.1371/journal.pone.0163886.t002
Albumin Effect on MRP2 and BCRP in the VT Assay
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substrate was seen for both substrates in the presence of 0.1% BSA (Fig 1). BSA increasedVmax
and Km of CDCF by roughly 110% and 63%, respectively, but the difference was statistically
significant only for Vmax (Table 3). The observed effect was reproducible with different MRP2
vesicle batches.
The uptake of endogenous estradiol metabolite, E217βG, is known to exhibit sigmoidal
kinetics in vesicles suggesting two binding sites on MRP2 [32, 33]. The sigmoidal kinetics was
maintained after addition of BSA, but both the Vmax and Km increased, 55% and 36%, respec-
tively (Table 3). Both Km values were lower than the previously reported E217βGKm that range
from 94 to 150 μM [33, 35–37].
We selected Lucifer Yellow as a probe substrate to study BSA effects on BCRP transport as
it is easily detected and used in commercial vesicular transport assay kits (SOLVO Biotechnol-
ogy, Szeged, Hungary and GenoMembrane, Kanagawa, Japan). The presence of 0.1% BSA pro-
duced a small, but statistically significant increase of 28% in maximal LY uptake by BCRP (Fig
1, Table 3). As with MRP2, there was no significant change in Km values. Since cholesterol is
known to potentiate BCRP-mediated transport [38], we used BCRP vesicles loaded with cho-
lesterol to observe the effect of BSA on highly active BCRP. However, no significant difference
was detected in the effect of 0.1% BSA on LY uptake in the assays between cholesterol loaded
and non-treated BCRP vesicles (Fig 2).
Our in-house vesicle transport assays have been optimized to use lower protein amounts in
the MRP2 assay than in the BCRP assay. In order to examine the sensitivity of the BSA effect to
Fig 1. The effect of 0.1% BSA on uptake kinetics. Uptake of (A) 5(6)-carboxy-2’,7’-dichlorofluorescein (CDCF) in MRP2 vesicles, (B) Estradiol-17-
β-glucuronide (E217βG) in MRP2 vesicles and (C) Lucifer Yellow (LY) in BCRP vesicles in the absence (control, open circles) and presence of 0.1%
BSA (closed circles). All assays were performed in triplicate and each point represents the mean (± SD) of 2–4 separate experiments normalized to
the calculated Vmax of the control. Curves represent the results from model fitting (see Materials and Methods).
doi:10.1371/journal.pone.0163886.g001
Table 3. Kinetic parameters of substrate uptake into vesicles in the presence and absence of 0.1% bovine serum albumin (BSA). Parameters
were calculated based on data from 2–4 separate experiments with GraphPad Prism and are reported as the best fit value (± standard error).
Transporter—substrate Km (μM) Vmax in the presence of 0.1% BSA (%) a
without BSA with 0.1% BSA
MRP2 –CDCF 9.6 (± 1.6) 15.6 (± 3.6) 210.4 (± 21.1) **
MRP2 –E217Βg 56.7 (± 8.2) 77.2 (± 7.4) 154.7 (± 9.9) *
BCRP–LY 31.2 (± 3.2) 33.5 (± 5.1) 127.5 (± 6.2)**
a The calculated Vmax in the absence of BSA was set at 100%. For details see Materials and Methods
* p < 0.01 and
** p < 0.001 compared to the Vmax in the absence of BSA
doi:10.1371/journal.pone.0163886.t003
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protein concentration, we tested the MRP2 and BCRP vesicles using three different protein
amounts. For both transporters, the magnitude of BSA effect decreased as the protein amount
increased (Fig 3).
To determine whether the albumin effect is dependent on the BSA concentration, we com-
pared CDCF and LY uptake in presence of 0.1 and 1.0% BSA. The higher BSA concentration
resulted in a larger uptake only at the highest tested CDCF concentration (Fig 4, left panel). In
contrast, at the lowest LY concentration, 0.1% BSA had a larger effect on the transport than 1%
BSA.
Inhibition of transport by oleic acid
The exact mechanism of the albumin effect on metabolic enzymes like UGTs and CYPs is
unknown, but as one key physiological role of albumin is the transport of fatty acids, it is pro-
posed that albumin binds inhibitory free long chain fatty acids that are liberated from cell
membranes during the production of membrane vesicles [27, 39–42]. For a similar mechanism
of action to be applied in the case of ABC transporters, it would require that the fatty acids
present in the vesicle preparation have an inhibitory potential on MRP2 and BCRP. In the case
Fig 2. The effect of 0.1% bovine serum albumin (BSA) in BCRP vesicles not loaded with cholesterol. Uptake of Lucifer Yellow (LY) into
BCRP vesicles not loaded with cholesterol is shown in the absence (control, open circles) and presence (closed circles) of 0.1% BSA. The Vmax of
control was set to 100% and the results normalized to this. Each point represents the mean ± SD, n = 3. Black solid curves represent the fitting of
the data for vesicles without cholesterol loading and grey dashed curves represent the corresponding fitting from cholesterol loaded vesicles.
doi:10.1371/journal.pone.0163886.g002
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of Sf9 cells that we have used, the most abundant fatty acid is oleic acid, comprising 48% of the
lipid composition [43].
Oleic acid decreased the uptake of substrates in bothMRP2 and BCRP vesicles in a concen-
tration dependent manner (Fig 5). However, since fatty acids can interfere with the membrane
vesicles and exert their apparent inhibitory effect by disturbing the vesicle structure [44], we
studied retention of the substrate in the vesicles after inhibition of the transporters with sodium
orthovanadate and subsequent addition of oleic acid. In MRP2 vesicles, the CDCF retention
after the addition of oleic acid followed the decrease in uptake observed in the inhibition assay
Fig 3. Relationship between the albumin effect and amount of vesicles used in the assay. Transport activity with varying amount of vesicles
(measured as total protein in μg per well) were examined in the presence and absence of 0.1% BSA. Substrate concentrations in the assay were
(left panel) 50 μM for CDCF (MRP2 vesicles) and (right panel) 200 μM for Lucifer Yellow (BCRP vesicles). Data is expressed as relative transport,
normalized to the ATP-dependent uptake in the absence of BSA. Each bar represents the mean (± SD), n = 3–6.
doi:10.1371/journal.pone.0163886.g003
Fig 4. The comparison of 0.1% and 1.0% BSA effect on uptake kinetics. (Left panel) CDCF uptake into MRP2 vesicles, (right panel)
Lucifer Yellow (LY) uptake into BCRP vesicles. Each bar represents the mean (± SD) of 2–3 separate experiments. The uptake rate of the
control (0% BSA) was set to 100% and uptake rates in the presence of 0.1% and 1.0% BSA were normalized to control. * p < 0.05 and **
p < 0.01 compared to the uptake in the absence of BSA.
doi:10.1371/journal.pone.0163886.g004
Albumin Effect on MRP2 and BCRP in the VT Assay
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(Fig 5, left panel). This suggests that the observed inhibitory effect of oleic acid on MRP2 is due
to the breakage of vesicles. The cholesterol-loaded BCRP vesicles were less affected by oleic
acid, even though at increasing oleic acid concentration, less LY was retained in the vesicles
(Fig 5, right panel).
Discussion
Our results show that the BSA effect for MRP2 and BCRP is displayed mainly through changes
in Vmax. This is in contrast to the results obtained with the metabolic enzymes where a decrease
in Km is usually the most pronounced effect of albumin [27, 28, 39–42, 45, 46]. Instead, trans-
porter-mediated uptake of both CDCF and LY showed a slight increase in Km in the presence
of BSA, although the change was not statistically significant. An increase in (unbound) Km
with albumin has earlier been noted for UGT1A1 3-glucuronidation of estradiol in human
liver microsomes [47] and UGT1A4 N2-glucuronidation of lamotrigine in recombinant
UGT1A4 expressed in HEK293 [28], but the reason for this deviating behavior is unknown.
The effect of BSA in this study was lower for MRP2 and BCRP (maximum 3-fold) than
what has previously been reported for metabolic enzymes. Albumin caused a> 20-fold decrease
in the Km of 6-hydroxyindole metabolism by UGT2A1 [48] as well as 10- and 7-fold increase in
affinity of zidovudine and lamotrigine to UGT2B7 [28, 45]. Manevski et al. [48] also reported an
up to 7-fold increase in Vmax of entacapone metabolism by UGT1A7. The effect of albumin that
is observedon the efflux transporter activity is more comparable to the results obtained with
CYPs, where albumin decreased the Km of phenytoin and paclitaxel hydroxylation in human
liver microsomes by 4- and 3-fold respectively [27, 41]. The smaller effect observed for the efflux
transporters could result from the lower albumin concentration used here (1.0%), than in many
of the metabolic studies that use higher albumin concentrations, up to 2%. At lower concentra-
tions, like the 0.1 and 1.0% albumin concentration used in our studies, the albumin effect is often
less pronounced for the metabolic enzymes than at higher albumin concentrations [39, 40, 46,
48]. However, in our work, the addition of 1.0% BSA did not increase substrate uptake except in
Fig 5. Inhibition of 5 μM CDCF uptake into MRP2 vesicles and 50 μM LY uptake into BCRP vesicles by oleic acid. Data is
presented as a relative transport activity normalized to uptake in the absence of oleic acid. Small, closed circles show results from
inhibition studies and larger black/white circles represent the retention of CDCF or LY in vesicles in studies on unspecific membrane
effects of oleic acid (for details see Materials and Methods). All data points were assayed in triplicate and curve fitting was performed
using the four parameter logistic equation. Graphs show the results from a representative experiment and data is represented as
mean ± SD. IC50 (95% confidence interval) for BCRP was 28.2 μM (21.7–37.7). In the case of MRP2, the IC50 was not applicable.
doi:10.1371/journal.pone.0163886.g005
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the highest substrate concentration for MRP2. In contrast, the 0.1% BSA enhanced LY uptake
more than 1.0% BSA, when the LY concentration was low (5μM).
BSA has a slightly larger effect with the studiedMRP2 assay than the BCRP assay, but that
might be due to the different protein amounts used in the assays. In our assays, the total amount
of protein in theMRP2 and BCRP vesicles were 7.5 μg and 50 μg, respectively. However, the direct
comparison of vesicle amounts betweenMRP2 and BCRPwould not be feasible since the vesicle
preparations are not the same. Moreover, we investigated if the cholesterol treatment could cause
the observeddifferences. Apart from changing the properties of the membrane, cholesterol addi-
tionmay remove some of the free fatty acids or other lipophilic compounds in the vesicle prepara-
tion through binding to the cyclodextrincomplex used to solubilize cholesterol during cholesterol
loading.However, as the cholesterol loading does not appear to influence the observedBSA effect
in BCRP vesicles, it is unlikely that it would cause the difference betweenBCRP andMRP2 either.
It is possible that the difference in the BSA effect on theMRP2 and BCRP assays are due to sub-
strate- or transporter-dependency, as has been observed for UGTs [48].
Albumin is proposed to influence the activity of metabolic enzymes through binding of
inhibitory free fatty acids that originate from the vesicles. Oleic acid, the most abundant fatty
acid in Sf9 cells, was able to inhibit BCRP transport activity, but our assay was unsuitable to
investigate the effect of oleic acid on MRP2, since oleic acid interfered with the membrane
integrity of MRP2 vesicles. The calculated IC50 value for BCRP, 28.2 μM, should be considered
as an apparent value, because the concentration of oleic acid inherently present in the vesicle
preparation is unknown and high concentrations of oleic acid interferes with the membrane
structure of the cholesterol-loaded BCRP vesicles. High concentration (> 1 mM) of oleic acid
was previously reported to decrease BCRP-mediated transport of mitoxantrone in Caco-2 cells
[49] and rosuvastatin in sandwich-cultured hepatocytes [50], but we are unaware of previous
reports on the interaction between oleic acid and MRP2. Based on our results, the free oleic
acid present in the vesicle preparations could weakly inhibit BCRP and removal of free fatty
acids by addition of BSA could lead to the effect of BSA observedon BCRP.
In summary, we have shown that the addition of BSA to the vesicular transport assay has an
effect on the maximal uptake rate of MRP2 and BCRP substrates. Oleic acid inhibited BCRP,
which is in line with the proposedmechanism behind the albumin effect on metabolic
enzymes. The inhibitory effect of oleic acid on MRP2 could not be investigated, as oleic acid
damaged the MRP2 vesicles. The effect of BSA on substrate uptake was dependent on the vesi-
cle amount, determined by protein concentration, while increasing BSA concentration did not
significantly improve substrate uptake. Even though albumin clearly has an effect in the vesicle
transport assay, it may not have a very large effect on the estimated clearance of transporter
substrates. Since both Vmax and Km values of the substrates increased in our study, the calcu-
lated transportermediated clearance would be only slightly altered (30% higher) compared to
conditions without BSA, considering linear kinetics where clearance is the ratio of Vmax to Km.
Such small alterations in clearance are unlikely to have a major role in in vitro—in vivo predic-
tions of the MRP2- and BCRP -mediated transport, as they are easily lost in other variability
such as inter-laboratory variation. However, as the albumin effect has been observed to be both
transporter- and substrate-dependent for the metabolic enzymes, it may have a larger impact
with other substrates and/or transporters and should therefore be kept in mind when BSA is
included in the vesicular assay for example as a solubilizer.
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